CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pacira Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pacira Biosciences Inc
5401 West Kennedy Boulevard, Suite 890
Phone: (813) 553-6680p:813 553-6680 TAMPA, FL  33609  United States Ticker: PCRXPCRX

Business Summary
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Paul J.Hastings 63 1/2/2024 6/2/2011
Chief Executive Officer, Director Frank D.Lee 56 1/2/2024 1/2/2024
Chief Financial Officer Charles A.Reinhart 62 5/3/2016 5/3/2016
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MyoScience, Inc. 1600 Seaport Blvd. Redwood City CA United States
PACIRA PHARMACEUTICALS INC 3535 RIVIERA DR SAN DIEGO CA US

Business Names
Business Name
82P
Flexion Therapeutics Inc
MyoScience, Inc.
7 additional Business Names available in full report.

General Information
Number of Employees: 711 (As of 12/31/2023)
Outstanding Shares: 46,523,185 (As of 4/15/2024)
Shareholders: 11
Stock Exchange: NASD
Federal Tax Id: 510619477
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024